Malignant Neoplasm — Trials

Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20,116
Recruiting: 10,894
Ph III recruiting: 1,280
Growth YoY: +12%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11,163)

clinicaltrialsPublishedShowing 251–300 of 90,685 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03187288	Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS	completed	Phase 1	13	University Health Network, TorontoOTHER	1	Sep 29, 2026	clinicaltrials
NCT03358472	Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)	completed	Phase 3	89	Incyte CorporationINDUSTRY	14	Sep 29, 2026	clinicaltrials